Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA7 Apr 2009Cited by 83 (Europe PMC)

PMID19350340DOI10.1007/s00198-009-0917-yPepBankPUB-19350340

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with glucocorticoid-induced osteoporosis, teriparatide increased lumbar spine BMD more than alendronate.
In plain wordsIn postmenopausal women with steroid-related osteoporosis, teriparatide increased lower spine bone density more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in postmenopausal women
Study
n = 277
Comparator
Alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
7.8%
teriparatide, postmenopausal women
Lumbar spine BMD increase
3.7%
alendronate, postmenopausal women
Source sentences
Summary
At 18 months, mean percent increases from baseline in lumbar spine BMD were significantly greater in the teriparatide versus alendronate group in postmenopausal women (7.8% versus 3.7%, p < 0.001), premenopausal women (7.0% versus 0.7%, p < 0.001), and men (7.3% versus 3.7%, p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome was change in lumbar spine BMD.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034001
02HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide increased lumbar spine BMD more than alendronate.
In plain wordsIn men with steroid-related osteoporosis, teriparatide increased lower spine bone density more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in men
Study
n = 83
Comparator
Alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
7.3%
teriparatide, men
Lumbar spine BMD increase
3.7%
alendronate, men
Source sentences
Summary
At 18 months, mean percent increases from baseline in lumbar spine BMD were significantly greater in the teriparatide versus alendronate group in postmenopausal women (7.8% versus 3.7%, p < 0.001), premenopausal women (7.0% versus 0.7%, p < 0.001), and men (7.3% versus 3.7%, p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome was change in lumbar spine BMD.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034003
03HumanRandomized controlled trialEfficacy outcome
In premenopausal women with glucocorticoid-induced osteoporosis, teriparatide increased lumbar spine BMD more than alendronate.
In plain wordsIn premenopausal women with steroid-related osteoporosis, teriparatide increased lower spine bone density more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in premenopausal women
Study
n = 67
Comparator
Alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
7%
teriparatide, premenopausal women
Lumbar spine BMD increase
0.7%
alendronate, premenopausal women
Source sentences
Summary
At 18 months, mean percent increases from baseline in lumbar spine BMD were significantly greater in the teriparatide versus alendronate group in postmenopausal women (7.8% versus 3.7%, p < 0.001), premenopausal women (7.0% versus 0.7%, p < 0.001), and men (7.3% versus 3.7%, p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome was change in lumbar spine BMD.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034002
04HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, vertebral fractures occurred in one teriparatide patient and ten alendronate patients.
In plain wordsIn steroid-related osteoporosis, fewer patients had spine fractures with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadiographic vertebral fractures
Study
n = 427
Comparator
Alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Patients with radiographic vertebral fractures
1 patients
teriparatide
Patients with radiographic vertebral fractures
10 patients
alendronate
Source sentences
Summary
Radiographic vertebral fractures occurred in one teriparatide (one postmenopausal) and ten alendronate patients (six postmenopausal, four men),
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034004
05HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, nonvertebral fractures occurred in 12 teriparatide patients versus eight alendronate patients.
In plain wordsIn steroid-related osteoporosis, more patients had fractures outside the spine with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNonvertebral fractures
Study
n = 427
Comparator
Alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Patients with nonvertebral fractures
12 patients
teriparatide
Patients with nonvertebral fractures
8 patients
alendronate
Source sentences
Summary
and nonvertebral fractures occurred in 12 teriparatide (nine postmenopausal, two premenopausal, one man) and eight alendronate patients (six postmenopausal, two men).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034006
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with glucocorticoid-induced osteoporosis, vertebral fractures occurred in one teriparatide patient and six alendronate patients.
In plain wordsIn postmenopausal women with steroid-related osteoporosis, fewer patients had spine fractures with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadiographic vertebral fractures in postmenopausal women
Study
n = 277
Comparator
Alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/day · 18 monthsAs given in this study (human).
Measurements
Postmenopausal women with radiographic vertebral fractures
1 patients
teriparatide, postmenopausal women
Postmenopausal women with radiographic vertebral fractures
6 patients
alendronate, postmenopausal women
Source sentences
Summary
Radiographic vertebral fractures occurred in one teriparatide (one postmenopausal) and ten alendronate patients (six postmenopausal, four men),
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034005
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with glucocorticoid-induced osteoporosis, nonvertebral fractures occurred in nine teriparatide patients versus six alendronate patients.
In plain wordsIn postmenopausal women with steroid-related osteoporosis, nine teriparatide patients and six alendronate patients had fractures outside the spine.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedNonvertebral fractures in postmenopausal women
Study
n = 277
Comparator
Alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
and nonvertebral fractures occurred in 12 teriparatide (nine postmenopausal, two premenopausal, one man) and eight alendronate patients (six postmenopausal, two men).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034007
08HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, nonvertebral fractures occurred in one teriparatide patient versus two alendronate patients.
In plain wordsIn men with steroid-related osteoporosis, one teriparatide patient and two alendronate patients had fractures outside the spine.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedNonvertebral fractures in men
Study
n = 83
Comparator
Alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
and nonvertebral fractures occurred in 12 teriparatide (nine postmenopausal, two premenopausal, one man) and eight alendronate patients (six postmenopausal, two men).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034009
09HumanRandomized controlled trialEfficacy outcome
In premenopausal women with glucocorticoid-induced osteoporosis, two teriparatide patients had nonvertebral fractures.
In plain wordsIn premenopausal women with steroid-related osteoporosis, two teriparatide patients had fractures outside the spine.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableNonvertebral fractures in premenopausal women
Study
n = 67
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
and nonvertebral fractures occurred in 12 teriparatide (nine postmenopausal, two premenopausal, one man) and eight alendronate patients (six postmenopausal, two men).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
Report a problemFND-1935034008

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In glucocorticoid-induced osteoporosis, adverse event proportions with teriparatide versus alendronate were consistent across sex and menopausal subgroups.
In plain wordsIn steroid-related osteoporosis, adverse event proportions with teriparatide versus alendronate were consistent across sex and menopausal groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedAdverse event proportions across subgroups
Study
n = 427
Comparator
Alendronate
Analysis
Secondary
Outcome group
Adverse events · Whole body
Source sentences
Summary
The proportion of patients reporting adverse events in teriparatide versus alendronate groups was consistent across subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety.
Summary · context
This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1935034010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Summary

Results from this study10

Studies that did not test the peptide alone1

Version history

Subjects

Publication types

MeSH terms